abstract: @entity8 ( @entity8 ) is a rare, progressive, multi-system, @entity1 of telomere biology, first described in 1906 as the @entity8 . The condition presents with the classic triad of @entity7 , @entity3 . Variable somatic abnormalities may be present; these include pulmonary, gastrointestinal, genitourinary, cerebral, and dental complications. @entity6 eventually develops, progressing to @entity4 . In our @entity0 , the progression of @entity8 did not follow the "classic triad" typically seen in the condition. Here we report the case of a 27-year-old male who had features consistent with this syndrome but who had a normal oral cavity associated with @entity5 for @entity7 and @entity3 were the dominant clinical features. The @entity0 was advised to avoid smoking and severe exposure to the sun, and to return regularly for follow-up. Because all symptoms of this disorder are not necessarily seen collectively in any one @entity0 , physicians should consider it as a probability in all @entity0 showing signs of @entity2 , especially accompanied by @entity5 . Our report emphasizes the fact that not all components of the syndrome need to be present and in all cases of genodermatosis, pleomorphism may be expected with variable clinical manifestations. Even though many variants have been described in literature, sparing of the oral cavity as in our @entity0 is extremely uncommon. Therefore, physicians should be aware of the mucocutaneous manifestation of @entity8 and its diagnosis and refer the @entity0 for better evaluation.

title: XXXX Without Oral Involvement: A Rare @entity1 .

answer: @entity8


abstract: UNASSIGNED: Ebola virus (EBOV) causes a severe @entity3 with a deficient immune response, @entity2 and lymphocyte apoptosis. Dendritic cells (DC), which trigger the adaptive response, do not mature despite EBOV @entity1 . We recently demonstrated that DC maturation is unblocked by disabling the innate response antagonizing domains (IRADs) in EBOV VP35 and VP24 by mutations @entity4 and @entity5 , respectively. Here we analyzed the effects of VP35 and VP24 with the IRADs disabled on global gene expression in @entity0 DC. @entity0 monocyte-derived DC were infected by wild-type EBOV (wt EBOV), or EBOVs carrying the mutation in VP35 (EBOV/VP35m), VP24 (EBOV/VP24m), or both (EBOV/VP35m/VP24m). Global gene expression at 8 and 24 hrs was analyzed by deep sequencing, and the expression of interferon (IFN) subtypes up to 5 days post- @entity1 was analyzed by quantitative RT-PCR (qRT-PCR). Wt EBOV induced a weak global gene expression response, including markers of DC maturation, cytokines, chemokines, chemokine receptors, and multiple IFN. The VP35 mutation unblocked the expression resulting in a dramatic increase in expression of these transcripts at 8 and 24 hrs. Surprisingly, DC infected with EBOV/VP24m expressed lower levels of many of these transcripts at 8 hrs after @entity1 , compared to wt EBOV. In contrast, at 24 hrs, expression of the transcripts increased in DC infected with any of the three mutants, as compared to wt EBOV. Moreover, sets of genes affected by the two mutations only partially overlapped. Pathway analysis demonstrated that the VP35 mutation unblocked pathways involved in antigen processing and presentation, and IFN signaling. These data suggest EBOV IRADs have profound effects on the host adaptive immune response through massive transcriptional downregulation of DC. IMPORTANCE: The study shows that @entity1 of DC with EBOV, but not its mutant forms with VP35 and/or VP24 IRADs disabled, causes the global block in expression of host genes. The temporal effects of mutations disrupting the two IRADs differ, and the lists of affected genes only partially overlap such that VP35 and VP24 IRADs each have profound effects on antigen presentation by exposed DC. The global modulation of DC gene expression and the resulting lack of their maturation represent a major mechanism by which EBOV disables the T cell response, and suggests that these suppressive pathways are a therapeutic target that may unleash the T cell responses during EBOV @entity1 .

title: Different temporal effects of Ebola virus VP35 and VP24 proteins on the global gene expression in XXXX dendritic cells.

answer: @entity0


abstract: UNASSIGNED: Prion diseases are @entity3 associated with the conversion of cellular prion protein ( @entity12 ) into its aberrant infectious form ( @entity12 (Sc)). There is no treatment available for these diseases. The bile acids @entity15 ( @entity15 ) and @entity14 ( @entity18 ) have been recently shown to be neuroprotective in other protein misfolding disease models including @entity4 , @entity9 , and also in @entity0 with @entity7 ( @entity7 ). Here we studied the therapeutic efficacy of these compounds in @entity8 . We demonstrated that @entity15 and @entity18 substantially reduced @entity12 conversion in cell-free aggregation assays as well as in chronically and acutely infected cell cultures. This effect was mediated through reduction of @entity12 (Sc) seeding ability, rather than an effect on @entity12 . We also demonstrated the ability of @entity15 and @entity18 to reduce @entity6 in prion @entity2 . @entity18 treatment reduced @entity13 and prolonged survival in RML prion-infected @entity1 . Interestingly, these effects were limited to the males, implying a gender-specific difference in drug metabolism. Beyond effects on @entity12 (Sc), we found that levels of phosphorylated @entity16 were increased at early time points, with correlated reductions in @entity17 . As demonstrated for other @entity3 , we now show that @entity15 and @entity18 may have a therapeutic role in @entity8 , with effects on both prion conversion and neuroprotection. Our findings, together with the fact that these natural compounds are orally bioavailable, permeable to the blood-brain barrier and FDA-approved for use in @entity0 , make these compounds promising alternatives for the treatment of @entity8 . IMPORTANCE: Prion diseases are @entity3 that are transmissible to @entity0 and other mammals. There are no disease-modifying therapies available, despite decades of research. Treatment targets have included @entity5 , clearance of toxic aggregates, and prevention of downstream neurodegeneration. No one target may be sufficient; rather, compounds which have a multi-modal mechanism, acting on different targets, would be ideal. @entity15 and @entity18 are @entity11 that may fulfill this dual role; previous studies have demonstrated their neuroprotective effects in several @entity3 models, and we now demonstrate that this effect occurs in @entity8 , with an added mechanistic target of upstream prion seeding. Importantly, these are natural compounds which are orally bioavailable, permeable to the blood-brain barrier and FDA-approved for use in @entity0 with @entity10 . They have recently been proven efficacious in @entity0 @entity7 . Therefore, these compounds are promising options for the treatment of @entity8 .

title: XXXX reduce prion conversion, reduce @entity6 , and prolong male survival in models of @entity8 .

answer: @entity11


abstract: UNASSIGNED: Prion diseases are @entity3 associated with the conversion of cellular prion protein ( @entity12 ) into its aberrant infectious form ( @entity12 (Sc)). There is no treatment available for these diseases. The bile acids @entity15 ( @entity15 ) and @entity14 ( @entity18 ) have been recently shown to be neuroprotective in other protein misfolding disease models including @entity4 , @entity9 , and also in @entity0 with @entity7 ( @entity7 ). Here we studied the therapeutic efficacy of these compounds in @entity8 . We demonstrated that @entity15 and @entity18 substantially reduced @entity12 conversion in cell-free aggregation assays as well as in chronically and acutely infected cell cultures. This effect was mediated through reduction of @entity12 (Sc) seeding ability, rather than an effect on @entity12 . We also demonstrated the ability of @entity15 and @entity18 to reduce @entity6 in prion @entity2 . @entity18 treatment reduced @entity13 and prolonged survival in RML prion-infected @entity1 . Interestingly, these effects were limited to the males, implying a gender-specific difference in drug metabolism. Beyond effects on @entity12 (Sc), we found that levels of phosphorylated @entity16 were increased at early time points, with correlated reductions in @entity17 . As demonstrated for other @entity3 , we now show that @entity15 and @entity18 may have a therapeutic role in @entity8 , with effects on both prion conversion and neuroprotection. Our findings, together with the fact that these natural compounds are orally bioavailable, permeable to the blood-brain barrier and FDA-approved for use in @entity0 , make these compounds promising alternatives for the treatment of @entity8 . IMPORTANCE: Prion diseases are @entity3 that are transmissible to @entity0 and other mammals. There are no disease-modifying therapies available, despite decades of research. Treatment targets have included @entity5 , clearance of toxic aggregates, and prevention of downstream neurodegeneration. No one target may be sufficient; rather, compounds which have a multi-modal mechanism, acting on different targets, would be ideal. @entity15 and @entity18 are @entity11 that may fulfill this dual role; previous studies have demonstrated their neuroprotective effects in several @entity3 models, and we now demonstrate that this effect occurs in @entity8 , with an added mechanistic target of upstream prion seeding. Importantly, these are natural compounds which are orally bioavailable, permeable to the blood-brain barrier and FDA-approved for use in @entity0 with @entity10 . They have recently been proven efficacious in @entity0 @entity7 . Therefore, these compounds are promising options for the treatment of @entity8 .

title: @entity11 reduce prion conversion, reduce XXXX , and prolong male survival in models of @entity8 .

answer: @entity6


abstract: UNASSIGNED: Prion diseases are @entity3 associated with the conversion of cellular prion protein ( @entity12 ) into its aberrant infectious form ( @entity12 (Sc)). There is no treatment available for these diseases. The bile acids @entity15 ( @entity15 ) and @entity14 ( @entity18 ) have been recently shown to be neuroprotective in other protein misfolding disease models including @entity4 , @entity9 , and also in @entity0 with @entity7 ( @entity7 ). Here we studied the therapeutic efficacy of these compounds in @entity8 . We demonstrated that @entity15 and @entity18 substantially reduced @entity12 conversion in cell-free aggregation assays as well as in chronically and acutely infected cell cultures. This effect was mediated through reduction of @entity12 (Sc) seeding ability, rather than an effect on @entity12 . We also demonstrated the ability of @entity15 and @entity18 to reduce @entity6 in prion @entity2 . @entity18 treatment reduced @entity13 and prolonged survival in RML prion-infected @entity1 . Interestingly, these effects were limited to the males, implying a gender-specific difference in drug metabolism. Beyond effects on @entity12 (Sc), we found that levels of phosphorylated @entity16 were increased at early time points, with correlated reductions in @entity17 . As demonstrated for other @entity3 , we now show that @entity15 and @entity18 may have a therapeutic role in @entity8 , with effects on both prion conversion and neuroprotection. Our findings, together with the fact that these natural compounds are orally bioavailable, permeable to the blood-brain barrier and FDA-approved for use in @entity0 , make these compounds promising alternatives for the treatment of @entity8 . IMPORTANCE: Prion diseases are @entity3 that are transmissible to @entity0 and other mammals. There are no disease-modifying therapies available, despite decades of research. Treatment targets have included @entity5 , clearance of toxic aggregates, and prevention of downstream neurodegeneration. No one target may be sufficient; rather, compounds which have a multi-modal mechanism, acting on different targets, would be ideal. @entity15 and @entity18 are @entity11 that may fulfill this dual role; previous studies have demonstrated their neuroprotective effects in several @entity3 models, and we now demonstrate that this effect occurs in @entity8 , with an added mechanistic target of upstream prion seeding. Importantly, these are natural compounds which are orally bioavailable, permeable to the blood-brain barrier and FDA-approved for use in @entity0 with @entity10 . They have recently been proven efficacious in @entity0 @entity7 . Therefore, these compounds are promising options for the treatment of @entity8 .

title: @entity11 reduce prion conversion, reduce @entity6 , and prolong male survival in models of XXXX .

answer: @entity8


abstract: OBJECTIVE: Socioeconomic status (SES) is a powerful predictor of @entity3 ( @entity3 ) and @entity4 . We examined the association in a large cohort of @entity0 with type 1 @entity1 . RESEARCH DESIGN AND METHODS: Clinical data from the Swedish National @entity1 Register were linked to national registers, whereby information on income, education, marital status, country of birth, comorbidities, and events was obtained. @entity0 were followed until a first incident event, @entity4 , or end of follow-up. The association between socioeconomic variables and the outcomes was modeled using Cox regression, with rigorous covariate adjustment. RESULTS: We included 24,947 @entity0 . Mean (SD) age and follow-up was 39.1 (13.9) and 6.0 (1.0) years. @entity3 occurred in 926 and 1378 individuals. Compared with being single, being married was associated with 50% lower risk of @entity4 , and @entity4 . Individuals in the two lowest quintiles had twice as great a risk of fatal/nonfatal @entity3 , @entity5 , and @entity2 and roughly three times as great a risk of @entity4 , @entity4 , and @entity3 as individuals in the highest income quintile. Compared with having  <=9 years of education, individuals with a college/university degree had 33% lower risk of @entity2 . Immigrants had 19%, 33%, and 45% lower risk of fatal/nonfatal @entity3 , all-cause @entity4 , and @entity4 , respectively, compared with Swedes. @entity0 had 44%, 63%, and 29% greater risk of all-cause @entity4 , @entity3 , and @entity4 . CONCLUSIONS: Low SES increases the risk of @entity3 and @entity4 by a factor of 2-3 in type 1 @entity1 .

title: Impact of Socioeconomic Status on XXXX and Mortality in 24,947 Individuals With Type 1 @entity1 .

answer: @entity3


abstract: OBJECTIVE: Socioeconomic status (SES) is a powerful predictor of @entity3 ( @entity3 ) and @entity4 . We examined the association in a large cohort of @entity0 with type 1 @entity1 . RESEARCH DESIGN AND METHODS: Clinical data from the Swedish National @entity1 Register were linked to national registers, whereby information on income, education, marital status, country of birth, comorbidities, and events was obtained. @entity0 were followed until a first incident event, @entity4 , or end of follow-up. The association between socioeconomic variables and the outcomes was modeled using Cox regression, with rigorous covariate adjustment. RESULTS: We included 24,947 @entity0 . Mean (SD) age and follow-up was 39.1 (13.9) and 6.0 (1.0) years. @entity3 occurred in 926 and 1378 individuals. Compared with being single, being married was associated with 50% lower risk of @entity4 , and @entity4 . Individuals in the two lowest quintiles had twice as great a risk of fatal/nonfatal @entity3 , @entity5 , and @entity2 and roughly three times as great a risk of @entity4 , @entity4 , and @entity3 as individuals in the highest income quintile. Compared with having  <=9 years of education, individuals with a college/university degree had 33% lower risk of @entity2 . Immigrants had 19%, 33%, and 45% lower risk of fatal/nonfatal @entity3 , all-cause @entity4 , and @entity4 , respectively, compared with Swedes. @entity0 had 44%, 63%, and 29% greater risk of all-cause @entity4 , @entity3 , and @entity4 . CONCLUSIONS: Low SES increases the risk of @entity3 and @entity4 by a factor of 2-3 in type 1 @entity1 .

title: Impact of Socioeconomic Status on @entity3 and Mortality in 24,947 Individuals With Type 1 XXXX .

answer: @entity1


abstract: A @entity3 -like state induced in @entity1 fed degraded carrageenan orally. By means of a combined semimacroscopic and histologic technique the course of the disease was followed during 28 days. The changes were primarily seen and became most prominent in the caecum. The first lesions were observed following 24 hours of treatment as small rounded foci initially with @entity0 in the surface epithelium, later forming superficial focal @entity2 . Ulcerative changes gradually progressed during the experiment, forming linear and later large, geographical @entity2 . Topographically the ulcerative process was strongly related to the larger submucosal vessels. Nonulcerated parts of the mucosa were not changed until following 7-14 days of treatment. The mucosa became bulging, granulated and finally villus-like. Accumulation of macrophages was found under the surface epithelium after 7-17 days. Possible pathogenetic mechanisms are discussed, especially the development of the early lesions and the significance of the macrophages.

title: Stereomicroscopic and histologic changes in the colon of XXXX fed degraded carrageenan.

answer: @entity1


abstract: We report a case of @entity6 in a 73-year-old @entity0 caused by @entity7 . The underlying cause was a @entity5 (6   *   3.3   *   3.8  cm) extending from the superior mucosal lip of Bauhin's valve. Abdominal ultrasonography showed a pathognomonic target-like mass appearing as multiple concentric rings. CT scan confirmed the diagnosis. Because of apparent obstruction, a laparotomy with right hemicolectomy and ileocolic anastomosis was performed. @entity3 most frequently occur in the cecum and ascending colon where they represent the most common submucosal @entity2 . They typically occur in elderly @entity0 with an incidence that varies from 0.15 to 0.56  %. @entity1 , @entity4 , and obstruction are typical symptoms. When faced with an intussusception in @entity0 , reduction with air per rectum can be performed. In adults, however, malignant cell spreading and seeding is of big concern. Since approximately 20-50  % of all underlying causes are malignant, explorative surgery is favored in adults.

title: Ileocolic Intussusception Caused by a Giant Ulcerating XXXX of Bauhin's Valve: an Unusual Cause of Intestinal Obstruction in the Adult.

answer: @entity3


abstract: Aim. @entity2 is a rare @entity1 caused by missense mutation leading to abnormal fibroblast and osteoblast proliferation and increased bone resorption. @entity10 can present in monostotic or @entity5 forms. About 3% of @entity10 could be in association with @entity5 ( @entity5 ). Because @entity10 is a rare disease, there is limited data in the literature about characteristics of disease and response to treatment. Methods. We present our five cases of @entity10 with general properties and their responses to medical treatment. Results. Two of our @entity0 had @entity5 and three had monostotic @entity10 . One of the @entity5 @entity0 had @entity5 . One of our @entity0 had surgery for femur @entity4 , @entity9 , and findings of compression. Four @entity0 were given @entity7 ; one was given @entity6 as @entity8 treatment. Bone @entity3 was relieved in all @entity0 with medical treatment. Conclusion. There was a decrease in bone turnover markers to some degree with medical treatment but no radiological improvement was observed.

title: Characteristics and Treatment Results of 5 @entity0 with XXXX and Review of the Literature.

answer: @entity2


abstract: Aim. @entity2 is a rare @entity1 caused by missense mutation leading to abnormal fibroblast and osteoblast proliferation and increased bone resorption. @entity10 can present in monostotic or @entity5 forms. About 3% of @entity10 could be in association with @entity5 ( @entity5 ). Because @entity10 is a rare disease, there is limited data in the literature about characteristics of disease and response to treatment. Methods. We present our five cases of @entity10 with general properties and their responses to medical treatment. Results. Two of our @entity0 had @entity5 and three had monostotic @entity10 . One of the @entity5 @entity0 had @entity5 . One of our @entity0 had surgery for femur @entity4 , @entity9 , and findings of compression. Four @entity0 were given @entity7 ; one was given @entity6 as @entity8 treatment. Bone @entity3 was relieved in all @entity0 with medical treatment. Conclusion. There was a decrease in bone turnover markers to some degree with medical treatment but no radiological improvement was observed.

title: Characteristics and Treatment Results of 5 XXXX with @entity2 and Review of the Literature.

answer: @entity0


abstract: @entity4 is rare during @entity5 . Most cases present in the immediate postoperative period with @entity6 or acute @entity3 are managed conservatively. But, inadvertent ligation of the main pancreatic duct with subsequent recurrent @entity3 and upstream dilatation of the pancreatic duct requiring a pancreatic ductal drainage operation has not been reported in the English literature. A 23-year-old female @entity0 presented with recurrent episodes of @entity2 for about 16  months. She had a history of type-1 @entity5 18  months back. She was evaluated with abdominal ultrasound and magnetic resonance cholangiopancreatography (MRCP). MRCP showed hugely dilated main pancreatic duct with normal hepaticojejunostomy @entity1 . There was no residual cyst. MRCP findings were suggestive of stricture of the main pancreatic duct due to previous surgery. Endoscopic pancreatic ductal decompression failed. The @entity0 was treated successfully with pancreaticogastrostomy. Postoperative recovery was uneventful. The @entity0 was well at 24-month follow-up.

title: Inadvertent ligation of the main pancreatic duct: an extremely rare complication of XXXX .

answer: @entity5


abstract: The area of decision making has much to offer in our effort to understand special populations. This pilot study is an example of just such a project, where we illustrate how traditional decision making tools and tasks can be used to uncover strengths and weaknesses within a growing population of young adults with @entity2 . In this pilot project we extended accounts of @entity1 such as those derived from "theory of mind" to predict key components of decision making in high-functioning young adults on the @entity2 spectrum. A battery of tests was administered to 15 high-functioning college students with @entity0 ( @entity0 ), focusing on decision making competence (DMC) and other aspects of decision making related to known deficits associated with @entity2 . Data from this group were compared to data from unselected college students receiving the same measures. First, as a test of a key social deficit associated with @entity2 , the target group scored much lower on the Empathy Quotient scale. Traditional elements of decision making competency such as Numeracy and application of decision rules were comparable across groups. However, there were differences in thinking style, with the @entity0 group showing lesser ability and engagement in intuitive thinking, and they showed lower levels of risk taking. For comparisons within the @entity0 group, autobiographical reports concerning individual lifestyles and outcomes were used to derive a scale of Social Functioning. The lowest scoring individuals showed the lowest levels of intuitive thinking, the lowest perceived levels of others' endorsement of socially undesirable behaviors, and the lowest ability to discriminate between "good" and "bad" risks. Results are discussed in terms of interventions that might aid high-functioning young adults with @entity0 in their everyday decision making.

title: Extending decision making competence to special populations: a pilot study of persons on the XXXX spectrum.

answer: @entity2


abstract: Among 3,242 coronary angiograms performed from November 1972 through October 1975 at the Massachusetts General Hospital, 175 @entity0 had normal coronary arteries or luminal narrowings of less than 30 per cent. All @entity0 were studied for @entity4 , and none had experienced prior @entity3 . Subsequent information was available in 159 @entity0 over a mean follow-up period of 42.7 months. There were no deaths, and only one @entity3 occurred during this period. However, among the @entity0 followed, continued @entity4 with episodes occurring at least once monthly was present in 54 per cent. In addition, 17 per cent of all @entity0 required subsequent hospitalization and 44 per cent continued to receive antianginal medication. Nearly half of the group (46 per cent) suffered some limitation of activity, and 22 per cent stated that they had either changed jobs or stopped work because of @entity4 . Continuing @entity4 was significantly more common in @entity0 and in @entity0 who had experienced @entity4 for more than one year before angiography. However, typicality of @entity4 for @entity5 or the occurrence of electrocardiographic changes of @entity1 prior to angiography did not predict continued @entity4 during the follow-up period. Thus, although mortality and morbidity are low in this group of @entity0 , the syndrome of @entity4 with angiographically insignificant @entity2 has an important impact on the lives of a majority of those affected.

title: XXXX with angiographically insignificant @entity2 . Clinical presentation and long-term follow-up.

answer: @entity4


abstract: Among 3,242 coronary angiograms performed from November 1972 through October 1975 at the Massachusetts General Hospital, 175 @entity0 had normal coronary arteries or luminal narrowings of less than 30 per cent. All @entity0 were studied for @entity4 , and none had experienced prior @entity3 . Subsequent information was available in 159 @entity0 over a mean follow-up period of 42.7 months. There were no deaths, and only one @entity3 occurred during this period. However, among the @entity0 followed, continued @entity4 with episodes occurring at least once monthly was present in 54 per cent. In addition, 17 per cent of all @entity0 required subsequent hospitalization and 44 per cent continued to receive antianginal medication. Nearly half of the group (46 per cent) suffered some limitation of activity, and 22 per cent stated that they had either changed jobs or stopped work because of @entity4 . Continuing @entity4 was significantly more common in @entity0 and in @entity0 who had experienced @entity4 for more than one year before angiography. However, typicality of @entity4 for @entity5 or the occurrence of electrocardiographic changes of @entity1 prior to angiography did not predict continued @entity4 during the follow-up period. Thus, although mortality and morbidity are low in this group of @entity0 , the syndrome of @entity4 with angiographically insignificant @entity2 has an important impact on the lives of a majority of those affected.

title: @entity4 with angiographically insignificant XXXX . Clinical presentation and long-term follow-up.

answer: @entity2


abstract: INTRODUCTION: MicroRNA-124 (miR-124) has been proven dysregulated in several @entity0 @entity2 and correlated with @entity2 progression. However, its expression and clinical significance in @entity3 ( @entity3 ) is still unclear. Thus, the aim of this study was to investigate the clinical significance of miR-124 expression in @entity3 . METHODS: Expression levels of miR-124 in 92 pairs of @entity3 and adjacent non- @entity2 tissues were detected by quantitative real-time PCR (qRT-PCR). In order to determine its prognostic value, overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. RESULTS: miR-124 expression level was significantly lower in @entity3 tissues compared with adjacent non- @entity2 tissues (P < 0.05). The 5-year OS of low miR-124 expression group was significantly shorter than that of high miR-124 expression group (P < 0.05). Moreover, the 5-year DFS of low miR-124 expression group was also significantly shorter than that of high miR-124 expression group (P < 0.05). In a multivariate Cox model, we found that miR-124 expression was an independent prognostic factor for both 5-year OS and 5-year DFS in @entity3 (P < 0.05). CONCLUSIONS: Our results offer the convincing evidence that miR-124 may play key roles in the progression of @entity1 and that the down-regulated expression of miR-124 may be independently associated with @entity4 and DFS of @entity0 , suggesting that miR-124 might be a potential marker for further risk stratification in the treatment of @entity1 .

title: Down-regulation of microRNA-124 is correlated with @entity2 metastasis and poor prognosis in @entity0 with XXXX .

answer: @entity1


abstract: INTRODUCTION: MicroRNA-124 (miR-124) has been proven dysregulated in several @entity0 @entity2 and correlated with @entity2 progression. However, its expression and clinical significance in @entity3 ( @entity3 ) is still unclear. Thus, the aim of this study was to investigate the clinical significance of miR-124 expression in @entity3 . METHODS: Expression levels of miR-124 in 92 pairs of @entity3 and adjacent non- @entity2 tissues were detected by quantitative real-time PCR (qRT-PCR). In order to determine its prognostic value, overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. RESULTS: miR-124 expression level was significantly lower in @entity3 tissues compared with adjacent non- @entity2 tissues (P < 0.05). The 5-year OS of low miR-124 expression group was significantly shorter than that of high miR-124 expression group (P < 0.05). Moreover, the 5-year DFS of low miR-124 expression group was also significantly shorter than that of high miR-124 expression group (P < 0.05). In a multivariate Cox model, we found that miR-124 expression was an independent prognostic factor for both 5-year OS and 5-year DFS in @entity3 (P < 0.05). CONCLUSIONS: Our results offer the convincing evidence that miR-124 may play key roles in the progression of @entity1 and that the down-regulated expression of miR-124 may be independently associated with @entity4 and DFS of @entity0 , suggesting that miR-124 might be a potential marker for further risk stratification in the treatment of @entity1 .

title: Down-regulation of microRNA-124 is correlated with XXXX metastasis and poor prognosis in @entity0 with @entity1 .

answer: @entity2


abstract: INTRODUCTION: MicroRNA-124 (miR-124) has been proven dysregulated in several @entity0 @entity2 and correlated with @entity2 progression. However, its expression and clinical significance in @entity3 ( @entity3 ) is still unclear. Thus, the aim of this study was to investigate the clinical significance of miR-124 expression in @entity3 . METHODS: Expression levels of miR-124 in 92 pairs of @entity3 and adjacent non- @entity2 tissues were detected by quantitative real-time PCR (qRT-PCR). In order to determine its prognostic value, overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. RESULTS: miR-124 expression level was significantly lower in @entity3 tissues compared with adjacent non- @entity2 tissues (P < 0.05). The 5-year OS of low miR-124 expression group was significantly shorter than that of high miR-124 expression group (P < 0.05). Moreover, the 5-year DFS of low miR-124 expression group was also significantly shorter than that of high miR-124 expression group (P < 0.05). In a multivariate Cox model, we found that miR-124 expression was an independent prognostic factor for both 5-year OS and 5-year DFS in @entity3 (P < 0.05). CONCLUSIONS: Our results offer the convincing evidence that miR-124 may play key roles in the progression of @entity1 and that the down-regulated expression of miR-124 may be independently associated with @entity4 and DFS of @entity0 , suggesting that miR-124 might be a potential marker for further risk stratification in the treatment of @entity1 .

title: Down-regulation of microRNA-124 is correlated with @entity2 metastasis and poor prognosis in XXXX with @entity1 .

answer: @entity0


abstract: This study aimed to evaluate the receptor activator of nuclear factor-kB (RANK) expression statuses of @entity3 ( @entity3 ) @entity0 , @entity4 ( @entity4 ), @entity4 ( @entity4 ), and normal esophageal tissues (NETs) in Chinese Han and Kazakh ethnic, as well as the correlation of RANK expression with clinicopathological characteristics. RANK immunohistochemical analysis was conducted to investigate the expression of RANK in 113 @entity3 , 36 @entity4 , 63 @entity4 , and 98 NETs from Han ethnic @entity0 and in 196 @entity3 and 76 NETs from Kazakh ethnic @entity0 . The associations of RANK expression with ethnic and clinicopathological characteristics were examined using   (2)-test. Upregulated RANK expression was detected in both Han and Kazakh ethnic @entity3 tissues, compared with NETs (P = 1.11*10(-5), 0.001, respectively). RANK expression was significantly increased during malignant transformation from normal epithelium into @entity4 (P = 2.84*10(-7)) and @entity4 (P = 7.83*10(-6)) tissues in Han ethnic @entity0 . The increased expression of RANK also correlated with lymph node @entity1 in Kazakh ethnic @entity3 @entity0 (P = 0.019). By contrast, no significant correlation existed between RANK expression and clinicopathological characteristics of Han ethnic @entity3 @entity0 . Furthermore, Kaplan-Meier survival analysis showed that @entity3 @entity0 with higher expression of RANK protein had significantly worse prognosis than @entity3 @entity0 with low or no expression (P = 0.001). In conclusion, this study is the first to identify RANK overexpression as a novel @entity2 marker in both Kazakh and Han ethnic @entity3 @entity0 . The results support the association of RANK with @entity3 across ethnicities. In summary, RANK could be a therapeutic target in @entity3 @entity0 .

title: RANK overexpression as a novel XXXX marker: validated immunohistochemical analysis of two different ethnicities.

answer: @entity2


abstract: BACKGROUND: @entity3 containing regimens have been proposed as potentially valuable alternatives for the treatment of @entity0 with @entity5 ( @entity5 ) or extensively @entity4 ( @entity4 ). METHODS: A systematic review and meta-analysis was conducted to assess the efficacy, safety and tolerability of @entity3 for @entity4 ( @entity4 ) treatment. We searched the Cochrane Controlled Trial Registry, PubMed, Embase, Science Citation Index Expanded (SCI) and China National Knowledge Infrastructure (CNKI), database up to May 2014 to identify studies providing data of the use of @entity3 for the treatment of @entity4 . RESULTS: The search yielded 15 studies (367 @entity0 ) including one randomized controlled trial (RCT), covering 239 @entity0 who could be evaluated for effectiveness; 83% [95% confidence interval (CI), 75-90%; I(2)=62.8%] had a favorable outcome, defined as either cure or treatment completion. The pooled rate of culture conversion was 89% (95% CI, 83-95%; I(2)=49.6%). Between the group receiving daily @entity3 doses of  <=600 or >600 mg, the mortality was considerably lower in @entity0 treated with less than 600 mg/day (P value <0.001). Of 367 @entity0 for whom data on safety was available, @entity2 (31%, 95% CI, 19-42%; I(2)=81.7%) and @entity1 (25%, 95% CI, 15-34%; I(2)=76.6%) were the main adverse effects. @entity0 receiving less than 600 mg/day were more likely to experience nervous system adverse events (P value <0.01). CONCLUSIONS: The available evidence suggests that @entity3 could be considered as a promising option as treatment of MDR/XDR @entity4 . Randomized trials are warranted to define the dose and frequency of administration.

title: Systematic review and meta-analysis of the efficacy and safety of therapy with XXXX containing regimens in the treatment of multidrug-resistant and extensively @entity5 .

answer: @entity3


abstract: BACKGROUND: @entity3 containing regimens have been proposed as potentially valuable alternatives for the treatment of @entity0 with @entity5 ( @entity5 ) or extensively @entity4 ( @entity4 ). METHODS: A systematic review and meta-analysis was conducted to assess the efficacy, safety and tolerability of @entity3 for @entity4 ( @entity4 ) treatment. We searched the Cochrane Controlled Trial Registry, PubMed, Embase, Science Citation Index Expanded (SCI) and China National Knowledge Infrastructure (CNKI), database up to May 2014 to identify studies providing data of the use of @entity3 for the treatment of @entity4 . RESULTS: The search yielded 15 studies (367 @entity0 ) including one randomized controlled trial (RCT), covering 239 @entity0 who could be evaluated for effectiveness; 83% [95% confidence interval (CI), 75-90%; I(2)=62.8%] had a favorable outcome, defined as either cure or treatment completion. The pooled rate of culture conversion was 89% (95% CI, 83-95%; I(2)=49.6%). Between the group receiving daily @entity3 doses of  <=600 or >600 mg, the mortality was considerably lower in @entity0 treated with less than 600 mg/day (P value <0.001). Of 367 @entity0 for whom data on safety was available, @entity2 (31%, 95% CI, 19-42%; I(2)=81.7%) and @entity1 (25%, 95% CI, 15-34%; I(2)=76.6%) were the main adverse effects. @entity0 receiving less than 600 mg/day were more likely to experience nervous system adverse events (P value <0.01). CONCLUSIONS: The available evidence suggests that @entity3 could be considered as a promising option as treatment of MDR/XDR @entity4 . Randomized trials are warranted to define the dose and frequency of administration.

title: Systematic review and meta-analysis of the efficacy and safety of therapy with @entity3 containing regimens in the treatment of multidrug-resistant and extensively XXXX .

answer: @entity5


abstract: The heart rate levels and the incidence and types of @entity5 ( @entity5 ) during the rehabilitation of 40 @entity0 with @entity1 , were compared with those during 24-hour ambulatory monitoring and during a symptom-limited exercise test. Thirty-six @entity0 were studied 3 months or later after a @entity2 and four @entity0 were studied after coronary bypass surgery. The last @entity0 suffered from moderate @entity4 . Peak heart rates during rehabilitation exceeded those during other activities in 34 out of 40 @entity0 . Half of the @entity0 reached even higher heart rate levels during the exercise test. Twenty-three @entity0 had PVC during rehabilitation; frequent, multiform or repetitive PVC occurred in nine of these. During the exercise test, 24 @entity0 had @entity5 , while @entity5 were observed on the ambulatory tape recording in 34 @entity0 . Frequent, multiform, and repetitive @entity5 occurred in eight @entity0 during exercise testing and in 20 @entity0 during monitoring. No relation was found between either the incidence or the type of @entity6 in individual @entity0 under these three conditions. Thus, selection of @entity0 with a high risk for @entity3 during rehabilitation is not feasible by either exercise testing or ambulatory tape recording.

title: Heart rate levels and XXXX during cardiac rehabilitation.

answer: @entity5


abstract: OBJECTIVE: To study the effectiveness and safety of anti- @entity2 B-cell antibody rituximab (RTX) in the treatment of @entity3 (MMP). METHODS: Retrospective analysis of six MMP @entity0 receiving RTX with or without concomitant immunosuppression. RTX was administered as a high dose regimen (1000 mg/infusion, day 0 and day 14/cycle). Five @entity0 received more than one cycle. Main outcome measure was the treatment response, defined as complete remission (CR) or partial remission (PR), monitored at 16 and 24 weeks. As secondary outcome measure, drug-related adverse events were evaluated. RESULTS: All @entity0 responded within 16 weeks. Initial treatment response vanished in five of six @entity0 at a mean of 10 months (   4.4 standard deviation [SD]). A second cycle was initiated thereafter (interval 12 months    6.4 SD) resulting in CR in two of five and PR in three of five @entity0 . One @entity0 stabilized only when additional immunosuppression was initiated. Mean follow up was 22 months (   8.2 SD).Two individuals experienced infusion reactions. CONCLUSIONS: Our study adds long-term data to the very limited experience with biologicals in MMP, indicating that RTX is a promising option for @entity0 with @entity1 . We report for the first time the high dose regimen of RTX applied in a consecutive series.

title: Rituximab preserves vision in XXXX .

answer: @entity3


abstract: OBJECTIVE: To determine whether or not @entity0 race and ethnicity affect sinonasal @entity1 survival. STUDY DESIGN: Retrospective database analysis. SETTING: National @entity1 Institute's Surveillance, Epidemiology, and End Results Database, 1988-2010. SUBJECTS AND METHODS: @entity2 cases were extracted according to site codes and histology recode-broad groupings. The cohort was used to calculate disease-specific survival in regard to race and ethnicity. Extracted data were further analyzed through direct comparisons and multivariable Cox regression models controlling for @entity0 , @entity1 , and treatment characteristics. RESULTS: Unadjusted survival curves for all @entity2 showed poorer disease-specific survival for black versus white @entity0 (P = .02), which was eliminated after controlling for @entity1 characteristics (hazard ratio: 1.02, P = .86). Specifically for @entity3 , significantly poorer disease-specific survival was found for both black (P = .01) and Hispanic (P = .01) @entity0 as compared with white @entity0 . Similarly, when controlling for @entity1 characteristics, the disease-specific survival disparity was eliminated for black (hazard ratio: 0.93, P = .59) and Hispanic @entity0 (hazard ratio: 1.01, P = .94). CONCLUSION: Black race is a risk factor for poorer disease-specific survival when all sinonasal histologic subtypes are examined together. Specifically for @entity3 , both black race and Hispanic ethnicity are risk factors for poorer disease-specific survival. When @entity1 characteristics are controlled for in this cohort, the survival disparity is eliminated, demonstrating that the disparity can be accounted for exclusively by more advanced disease at presentation, opposed to the more complex effect seen in other subsites of the head and neck.

title: XXXX : Racial and Ethnic Disparities in Survival-A Review of 4714 @entity0 .

answer: @entity2


abstract: OBJECTIVE: To determine whether or not @entity0 race and ethnicity affect sinonasal @entity1 survival. STUDY DESIGN: Retrospective database analysis. SETTING: National @entity1 Institute's Surveillance, Epidemiology, and End Results Database, 1988-2010. SUBJECTS AND METHODS: @entity2 cases were extracted according to site codes and histology recode-broad groupings. The cohort was used to calculate disease-specific survival in regard to race and ethnicity. Extracted data were further analyzed through direct comparisons and multivariable Cox regression models controlling for @entity0 , @entity1 , and treatment characteristics. RESULTS: Unadjusted survival curves for all @entity2 showed poorer disease-specific survival for black versus white @entity0 (P = .02), which was eliminated after controlling for @entity1 characteristics (hazard ratio: 1.02, P = .86). Specifically for @entity3 , significantly poorer disease-specific survival was found for both black (P = .01) and Hispanic (P = .01) @entity0 as compared with white @entity0 . Similarly, when controlling for @entity1 characteristics, the disease-specific survival disparity was eliminated for black (hazard ratio: 0.93, P = .59) and Hispanic @entity0 (hazard ratio: 1.01, P = .94). CONCLUSION: Black race is a risk factor for poorer disease-specific survival when all sinonasal histologic subtypes are examined together. Specifically for @entity3 , both black race and Hispanic ethnicity are risk factors for poorer disease-specific survival. When @entity1 characteristics are controlled for in this cohort, the survival disparity is eliminated, demonstrating that the disparity can be accounted for exclusively by more advanced disease at presentation, opposed to the more complex effect seen in other subsites of the head and neck.

title: @entity2 : Racial and Ethnic Disparities in Survival-A Review of 4714 XXXX .

answer: @entity0


abstract: BACKGROUND: @entity3 and intestinal metaplasia (IM) are @entity4 in the development of @entity3 . Histopathological assessment is based on the updated Sydney system and superordinate staging systems, operative link on @entity5 assessment (OLGA) and operative link on @entity5 assessment using IM (OLGIM), all requiring a biopsy from the incisura angularis (angulus). AIM: To determine the value of the angulus biopsy for the detection of @entity4 and @entity1 risk evaluation using OLGA and OLGIM prospectively. METHODS: Biopsies from antrum (2), angulus (1) and corpus (2) were obtained from 213 @entity0 (age 19-94   years, median 54   years, female to male ratio 138:75) undergoing upper endoscopy. Histological assessment according to the updated Sydney system, OLGA and OLGIM staging was performed by gastrointestinal pathologists. Statistical analysis used exact confidence limits for dichotomous variables and repeated measurement analysis of variance. RESULTS: 8% of the cases with @entity6 and 3% with IM (17 vs 6/213) would have been missed without the angulus biopsy. More @entity0 were diagnosed with a @entity4 when the angulus biopsy was considered (13.1%, CI 8.9% to 18.4%), but the grade of @entity2 , if present at both sides, did not vary significantly in angulus and antrum. OLGA and OLGIM scores dropped significantly when recalculated without the angulus (difference in means  SD 0.131  0.402 and 0.075  0.313, respectively). The impact on the identification of high-risk stages is limited. CONCLUSIONS: The angulus biopsy adds to the detection of mild @entity3 in particular. It allows identifying a small additional number of @entity0 with high-risk @entity5 .

title: Impact of the angulus biopsy for the detection of gastric @entity4 and XXXX risk assessment.

answer: @entity3


abstract: BACKGROUND: @entity3 and intestinal metaplasia (IM) are @entity4 in the development of @entity3 . Histopathological assessment is based on the updated Sydney system and superordinate staging systems, operative link on @entity5 assessment (OLGA) and operative link on @entity5 assessment using IM (OLGIM), all requiring a biopsy from the incisura angularis (angulus). AIM: To determine the value of the angulus biopsy for the detection of @entity4 and @entity1 risk evaluation using OLGA and OLGIM prospectively. METHODS: Biopsies from antrum (2), angulus (1) and corpus (2) were obtained from 213 @entity0 (age 19-94   years, median 54   years, female to male ratio 138:75) undergoing upper endoscopy. Histological assessment according to the updated Sydney system, OLGA and OLGIM staging was performed by gastrointestinal pathologists. Statistical analysis used exact confidence limits for dichotomous variables and repeated measurement analysis of variance. RESULTS: 8% of the cases with @entity6 and 3% with IM (17 vs 6/213) would have been missed without the angulus biopsy. More @entity0 were diagnosed with a @entity4 when the angulus biopsy was considered (13.1%, CI 8.9% to 18.4%), but the grade of @entity2 , if present at both sides, did not vary significantly in angulus and antrum. OLGA and OLGIM scores dropped significantly when recalculated without the angulus (difference in means  SD 0.131  0.402 and 0.075  0.313, respectively). The impact on the identification of high-risk stages is limited. CONCLUSIONS: The angulus biopsy adds to the detection of mild @entity3 in particular. It allows identifying a small additional number of @entity0 with high-risk @entity5 .

title: Impact of the angulus biopsy for the detection of gastric XXXX and @entity3 risk assessment.

answer: @entity4


abstract: UNASSIGNED: @entity0 noroviruses (HuNoVs) are positive-sense RNA viruses that can cause severe, highly infectious @entity3 . HuNoV outbreaks are frequently associated with recombination between circulating strains. Strain genotyping and phylogenetic analyses show that noroviruses often recombine in a highly conserved region near the junction of the viral polyprotein ( @entity4 ) and capsid ( @entity5 ) genes and occasionally within the RNA-dependent RNA polymerase (RdRP) gene. Although genotyping methods are useful for tracking changes in circulating viral populations, they only report the dominant recombinant strains and do not elucidate the frequency or range of recombination events. Furthermore, the relatively low frequency of recombination in RNA viruses has limited studies to cell culture or in vitro systems that do not reflect the complexities and selective pressures present in an infected organism. Using two @entity1 norovirus (MNV) strains to model @entity2 , we developed a microfluidic platform to amplify, detect, and recover individual recombinants following in vitro and in vivo @entity2 . One-step RT-PCR was performed in picoliter drops with primers that identified the wild-type and recombinant progenies and scanned for recombination breakpoints at approximately 1-kb intervals. We detected recombination between MNV strains at multiple loci spanning the viral protease, RdRP, and capsid ORFs and isolated individual recombinant RNA genomes that were present at a frequency of 1/300,000 or greater. This study is the first to examine norovirus recombination following @entity2 of an animal and suggests that the exchange of RNA among viral genomes in the infected host occurs in multiple locations and is an important driver of genetic diversity. IMPORTANCE: RNA viruses increase diversity and escape host immune barriers by genomic recombination. Studies from a number of viral systems indicate that recombination occurs via template switching by the virus-encoded RNA-dependent RNA polymerase (RdRP). However, factors that govern the frequency and positions of recombination in an infected organism remain largely unknown. This work leverages advances in the applied physics of drop-based microfluidics to isolate and sequence rare recombinants arising from the @entity2 of @entity1 with two distinct strains of @entity1 norovirus. This report is the first to detect and analyze norovirus recombination in an animal model.

title: Isolation and analysis of rare norovirus recombinants from co-infected XXXX using drop-based microfluidics.

answer: @entity1


abstract: BACKGROUND: The purpose of this study was to assess the dosimetric and clinical feasibility of volumetric modulated arc based hypofractionated stereotactic radiotherapy (RapidArc) treatment for large @entity3 ( @entity2 >10cc). MATERIALS AND METHODS: Ten @entity2 @entity0 were immobilized using BrainLab mask. They were subject to multimodality imaging (magnetic resonance and computed tomography) to contour target and organs at risk (brainstem and cochlea). Volumetric modulated arc therapy (VMAT) based stereotactic plans were optimized in Eclipse (V11) treatment planning system (TPS) using progressive resolution optimizer-III and final dose calculations were performed using analytical anisotropic algorithm with 1.5 mm grid resolution. All @entity2 presented in this study were treated with VMAT based HSRT to a total dose of 25Gy in 5 fractions (5fractions/ week). VMAT plan contains 2-4 non-coplanar arcs. Treatment planning was performed to achieve at least 99% of @entity1 volume (D99) receives 100% of prescription dose (25Gy), while dose to OAR's were kept below the tolerance limits. Dose-volume histograms (DVH) were analyzed to assess plan quality. Treatments were delivered using upgraded 6 MV un-flattened photon beam (FFF) from Clinac-iX machine. Extensive pretreatment quality assurance measurements were carried out to report on quality of delivery. Point dosimetry was performed using three different detectors, which includes CC13 ion-chamber, Exradin A14 ion-chamber and Exradin W1 plastic scintillator detector (PSD) which have measuring volume of 0.13 cm3, 0.009 cm3 and 0.002 cm3 respectively. RESULTS: Average @entity1 volume of @entity2 was 11.3cc (  4.8), and located in eloquent areas. VMAT plans provided complete @entity1 coverage with average conformity index of 1.06 (  0.05). OAR's dose were kept below tolerance limit recommend by American Association of Physicist in Medicine task group-101(brainstem V0.5cc < 23Gy, cochlea maximum < 25Gy and Optic pathway <25Gy). PSD resulted in superior dosimetric accuracy compared with other two detectors (p=0.021 for PSD.

title: Planning and Dosimetric Study of Volumetric Modulated Arc Based Hypofractionated Stereotactic Radiotherapy for XXXX - 6MV Flattening Filter Free Photon Beam.

answer: @entity3


abstract: @entity15 is an opportunistic @entity7 that is associated with high mortality in immunocompromised individuals. While rhinocerebral and pulmonary forms are most common, primary @entity5 is very uncommon. The stomach is the most commonly affected organ followed by the colon and ileum in alimentary @entity16 . We report a rare case of invasive @entity6 in a 50-year-old @entity1 gentleman with a history of chronic @entity12 presenting with complaints of @entity2 and distension of the abdomen for 6  days associated with @entity3 , @entity8 , @entity9 and @entity10 . At presentation, he was hemodynamically unstable, febrile with uncontrolled blood sugar level and had negative @entity11 serology. There was generalized guarding, @entity14 and distension of the abdomen and investigations confirmed perforative @entity4 . Upon exploration, there was solitary large 4   *   4  cm size perforated ulcer in the gastric body with greenish, greyish sloughed out mucosa within. Wedge resection of the ulcer with primary closure was performed. Histopathology revealed aseptate, broad, obtuse angled fungal hyphae, and invasive @entity15 was confirmed by special stains like Periodic acid-Schiff (PAS) and Gomori's @entity13 (GMS). Very few cases of invasive @entity6 associated with uncontrolled @entity1 and @entity12 have been reported in the literature. Delayed presentation of the @entity0 along with rapid progression to @entity7 resulted in the case fatality despite early surgical intervention and critical care management.

title: Invasive Gastric XXXX -a Case Report.

answer: @entity15


abstract: Currently little is known about how a mechanically coupled BMI system's actions are integrated into ongoing body dynamics. We tested a locomotor task augmented with a BMI system driving a robot mechanically interacting with a @entity0 under three conditions: control locomotion ( @entity1 ), "simple elastic load" (E) and "BMI with elastic load" (BMI/E). The effect of the BMI was to allow compensation of the elastic load as a function of the neural drive. Neurons recorded here were close to one another in cortex, all within a 200 micron diameter horizontal distance of one another. The interactions of these close assemblies of neurons may differ from those among neurons at longer distances in BMI tasks and thus are important to explore. A point process @entity2 ( @entity2 ), was used to examine connectivity at two different binning timescales (1 ms vs. 10 ms). We used @entity2 models to fit non-Poisson neural dynamics solely using other neurons' prior neural activity as covariates. Models at different timescales were compared based on Kolmogorov-Smirnov (KS) goodness-of-fit and parsimony. About 15% of cells with non-Poisson firing were well fitted with the neuron-to-neuron models alone. More such cells were fitted at the 1 ms binning than 10 ms. Positive connection parameters ("excitation" ~70%) exceeded negative parameters ("inhibition" ~30%). Significant connectivity changes in the @entity2 determined networks of well-fitted neurons occurred between the conditions. However, a common core of connections comprising at least ~15% of connections persisted between any two of the three conditions. Significantly almost twice as many connections were in common between the two load conditions (~27%), compared to between either @entity3 and the baseline. This local point process @entity2 identified neural correlation structure and the changes seen across task conditions in the @entity0 in this neural subset may be intrinsic to cortex or due to feedback and input reorganization in adaptation.

title: Adaptation to elastic loads and BMI robot controls during XXXX locomotion examined with point-process GLMs.

answer: @entity0


abstract: PURPOSE: To evaluate the rate of @entity4 and resulting @entity0 outcomes after treatment of displaced midshaft @entity2 . METHODS: Skeletally mature @entity0 with isolated, displaced midshaft @entity2 treated with or without surgery over a 16-month period were recruited. The minimum length of follow-up at study examination was 12  months. @entity0 outcomes were documented using the SICK (scapular malposition, inferomedial border prominence, @entity1 and malposition, and dyskinesis of @entity3 ) Scapula Rating Scale, the Simple Shoulder Test, 3 visual analog scales (VAS) for @entity1 , and shoulder range-of-motion and strength measurements. Of the 32 eligible @entity0 , 24 (75%) were successfully recruited. RESULTS: The mean @entity0 age was 46      17 years, with a mean length of follow-up at study evaluation of 1.7      1  years. Surgical fixation was performed in 12 @entity0 (50%). @entity4 was present in 37.5% of @entity0 (n  =  9). @entity0 with @entity4 had worse SICK scapula scores (5.8      2.2 vs 3.1     2.4, P  =  .01), worse Simple Shoulder Test scores (10.5      1.6 vs 11.7      0.8, P  =  .029), higher maximum VAS @entity1 scores (4.1      3.1 vs 0.97      1.2, P  =  .002), and worse average VAS @entity1 scores in the week before the examination (2.7      2.5 vs 0.2      0.4, P  <  .001) compared with @entity0 without @entity4 . Range of motion and abduction strength were similar between the groups. @entity4 developed in 1 @entity0 treated with surgery (8% [1 of 12]) compared with 8 @entity0 treated nonoperatively (67% [8 of 12]) (P  =  .009). CONCLUSIONS: @entity4 is common after displaced middle-third @entity2 , and these @entity0 have more @entity1 and worse functional outcomes compared with @entity0 without @entity4 . Surgical treatment may reduce a @entity0 's risk of @entity4 developing and improve short-term outcomes.

title: XXXX following displaced @entity2 of the middle clavicle.

answer: @entity4


abstract: PURPOSE: To evaluate the rate of @entity4 and resulting @entity0 outcomes after treatment of displaced midshaft @entity2 . METHODS: Skeletally mature @entity0 with isolated, displaced midshaft @entity2 treated with or without surgery over a 16-month period were recruited. The minimum length of follow-up at study examination was 12  months. @entity0 outcomes were documented using the SICK (scapular malposition, inferomedial border prominence, @entity1 and malposition, and dyskinesis of @entity3 ) Scapula Rating Scale, the Simple Shoulder Test, 3 visual analog scales (VAS) for @entity1 , and shoulder range-of-motion and strength measurements. Of the 32 eligible @entity0 , 24 (75%) were successfully recruited. RESULTS: The mean @entity0 age was 46      17 years, with a mean length of follow-up at study evaluation of 1.7      1  years. Surgical fixation was performed in 12 @entity0 (50%). @entity4 was present in 37.5% of @entity0 (n  =  9). @entity0 with @entity4 had worse SICK scapula scores (5.8      2.2 vs 3.1     2.4, P  =  .01), worse Simple Shoulder Test scores (10.5      1.6 vs 11.7      0.8, P  =  .029), higher maximum VAS @entity1 scores (4.1      3.1 vs 0.97      1.2, P  =  .002), and worse average VAS @entity1 scores in the week before the examination (2.7      2.5 vs 0.2      0.4, P  <  .001) compared with @entity0 without @entity4 . Range of motion and abduction strength were similar between the groups. @entity4 developed in 1 @entity0 treated with surgery (8% [1 of 12]) compared with 8 @entity0 treated nonoperatively (67% [8 of 12]) (P  =  .009). CONCLUSIONS: @entity4 is common after displaced middle-third @entity2 , and these @entity0 have more @entity1 and worse functional outcomes compared with @entity0 without @entity4 . Surgical treatment may reduce a @entity0 's risk of @entity4 developing and improve short-term outcomes.

title: @entity4 following displaced XXXX of the middle clavicle.

answer: @entity2


abstract: UNASSIGNED: ABSTRACT    Aim: To analyze the clinicopathological features of @entity5 ( @entity5 ) associated with Xp11.2 translocation/ @entity6 gene fusions (Xp11.2 @entity5 ) in our institution. MATERIALS _ METHODS: We screened 983 @entity5 specimens. @entity6 immunohistochemical staining and FISH assay confirmed 22 Xp11.2 RCCs out of 65 suspicious cases. Clinicopathological and treatment outcomes of 22 @entity0 were retrospectively analyzed. RESULTS: In total, 22 @entity0 included 13 females and nine males with a mean age of 27 years. Ten @entity0 showed gross @entity4 . Treatments included surgeries, immunotherapy and molecular-targeted therapy. Seven cases were at stage III/IV and four cases had tumor @entity3 or distant @entity1 . During a median follow-up of 34 months, 19 @entity0 were alive while three died of distant @entity1 . CONCLUSION: Xp11.2 @entity5 is rare and FISH proved a useful diagnostic tool. Surgical resection achieved favorable outcome for @entity2 . Adult @entity0 at advanced stage had poorer outcomes even with postoperative adjuvant therapy.

title: XXXX associated with Xp11.2 translocation/ @entity6 gene fusions: clinical experience and literature review.

answer: @entity5


abstract: UNASSIGNED: ABSTRACT    Aim: To analyze the clinicopathological features of @entity5 ( @entity5 ) associated with Xp11.2 translocation/ @entity6 gene fusions (Xp11.2 @entity5 ) in our institution. MATERIALS _ METHODS: We screened 983 @entity5 specimens. @entity6 immunohistochemical staining and FISH assay confirmed 22 Xp11.2 RCCs out of 65 suspicious cases. Clinicopathological and treatment outcomes of 22 @entity0 were retrospectively analyzed. RESULTS: In total, 22 @entity0 included 13 females and nine males with a mean age of 27 years. Ten @entity0 showed gross @entity4 . Treatments included surgeries, immunotherapy and molecular-targeted therapy. Seven cases were at stage III/IV and four cases had tumor @entity3 or distant @entity1 . During a median follow-up of 34 months, 19 @entity0 were alive while three died of distant @entity1 . CONCLUSION: Xp11.2 @entity5 is rare and FISH proved a useful diagnostic tool. Surgical resection achieved favorable outcome for @entity2 . Adult @entity0 at advanced stage had poorer outcomes even with postoperative adjuvant therapy.

title: @entity5 associated with Xp11.2 translocation/ XXXX gene fusions: clinical experience and literature review.

answer: @entity6


abstract: PURPOSE: @entity1 ( @entity1 ) is a public health problem. There is an effort to establish the genetic contributions to the development of @entity1 . One is matrix metalloproteinases, extracellular matrix degrading enzymes related to systemic @entity2 . However, the impact of @entity4 ( @entity4 ) genotypes on the development of @entity1 is unknown. Our aim was to determine whether @entity4 single nucleotide polymorphism (SNP) ( @entity4 @entity5 ) is related to susceptibility to @entity1 . MATERIAL AND METHODS: A total of 106 @entity0 with a history of @entity3 and 88 controls without a history of @entity3 were enrolled in this study. Genotypes were determined by restriction fragment length polymorphism analyses after polymerase chain reaction. RESULTS: Genotypes and allele frequencies of the @entity4 @entity5 SNP was not statistically different between the @entity0 and control groups (p  >  0.05). There was a statistical association between @entity1 index (AHI) and body mass index (BMI), and also between AHI and neck circumference (p  <  0.001). There was no association among the genotypes and AHI, neck circumference, or BMI (p  >  0.05). CONCLUSIONS: We found no association between @entity4 @entity5 SNP and @entity1 . Studies to investigate the role of other polymorphisms and expression of @entity4 gene will provide more information.

title: Lack of association of XXXX promoter gene polymorphism in obstructive @entity3 .

answer: @entity4


abstract: PURPOSE: @entity1 ( @entity1 ) is a public health problem. There is an effort to establish the genetic contributions to the development of @entity1 . One is matrix metalloproteinases, extracellular matrix degrading enzymes related to systemic @entity2 . However, the impact of @entity4 ( @entity4 ) genotypes on the development of @entity1 is unknown. Our aim was to determine whether @entity4 single nucleotide polymorphism (SNP) ( @entity4 @entity5 ) is related to susceptibility to @entity1 . MATERIAL AND METHODS: A total of 106 @entity0 with a history of @entity3 and 88 controls without a history of @entity3 were enrolled in this study. Genotypes were determined by restriction fragment length polymorphism analyses after polymerase chain reaction. RESULTS: Genotypes and allele frequencies of the @entity4 @entity5 SNP was not statistically different between the @entity0 and control groups (p  >  0.05). There was a statistical association between @entity1 index (AHI) and body mass index (BMI), and also between AHI and neck circumference (p  <  0.001). There was no association among the genotypes and AHI, neck circumference, or BMI (p  >  0.05). CONCLUSIONS: We found no association between @entity4 @entity5 SNP and @entity1 . Studies to investigate the role of other polymorphisms and expression of @entity4 gene will provide more information.

title: Lack of association of @entity4 promoter gene polymorphism in obstructive XXXX .

answer: @entity3


abstract: This study aimed to investigate the prognostic value of the number of involved lymph nodes (pN), number of removed lymph nodes (RLNs), lymph node ratio (LNR), number of negative lymph nodes (NLNs), and log odds of positive lymph nodes (LODDS) in @entity0 @entity1 . The records of 2,515 @entity0 @entity1 who received a mastectomy or breast-conserving surgery were retrospectively reviewed. The log-rank test was used to compare survival curves, and Cox regression analysis was performed to identify prognostic factors. The median follow-up time was 64.2 months, and the 8-year disease-free survival (DFS) and @entity2 ( @entity2 ) were 74.6% and 82.3%, respectively. Univariate analysis showed that pN stage, LNR, number of RLNs, and number of NLNs were significant prognostic factors for DFS and @entity2 (all, P < 0.05). LODDS was a significant prognostic factor for @entity2 (P = 0.021). Multivariate analysis indicated that pN stage and the number of NLNs were independent prognostic factors for DFS and @entity2 . A higher number of NLNs was associated with higher DFS and @entity2 , and a higher number of involved lymph nodes were associated with poorer DFS and @entity2 . @entity1 with a NLNs count > 9 had better survival (P < 0.001). Subgroup analysis showed that the NLNs count had a prognostic value in @entity1 with different pT stages and different lymph node status (log-rank P < 0.05). For @entity0 , pN stage and NLNs count have a better prognostic value compared to the RLNs count, LNR, and LODDS. Number of negative lymph nodes should be considered for incorporation into staging for @entity0 .

title: Number of negative lymph nodes should be considered for incorporation into staging for XXXX .

answer: @entity0


abstract: UNASSIGNED: @entity7 plus @entity9 followed by @entity10 is a common adjuvant treatment for high-risk @entity0 . It has been associated with @entity4 in several case reports. We describe three @entity1 in whom @entity5 developed immediately after the first @entity10 exposure and worsened clinically over time. All reported dyspnoea, @entity2 and progressive @entity8 . Imaging revealed diffuse @entity4 . Other causes of @entity11 were excluded with laboratory work-up, imaging, biopsy studies and results of antibiotic treatment. The @entity11 was reversed only after administration of high-dose @entity3 , an empirical treatment previously reported to be beneficial in similar cases. Although chemotherapy using concomitant or sequential drugs may make identification of the toxic agent difficult, we noted a clear temporal relationship between exposure to @entity10 and the development of @entity4 . Furthermore, according to the available literature, it is less likely that a @entity11 would be caused by either @entity9 or trastuzumab. In conclusion, clinicians should be aware of the potentially life-threatening risk of @entity4 following @entity10 treatment. If @entity10 is halted early and the @entity1 has good lung reserve, @entity4 can be reversed with high-dose @entity6 administration.

title: @entity10 -induced pneumonitis in @entity1 with XXXX : case series and review of the literature.

answer: @entity0


abstract: UNASSIGNED: @entity7 plus @entity9 followed by @entity10 is a common adjuvant treatment for high-risk @entity0 . It has been associated with @entity4 in several case reports. We describe three @entity1 in whom @entity5 developed immediately after the first @entity10 exposure and worsened clinically over time. All reported dyspnoea, @entity2 and progressive @entity8 . Imaging revealed diffuse @entity4 . Other causes of @entity11 were excluded with laboratory work-up, imaging, biopsy studies and results of antibiotic treatment. The @entity11 was reversed only after administration of high-dose @entity3 , an empirical treatment previously reported to be beneficial in similar cases. Although chemotherapy using concomitant or sequential drugs may make identification of the toxic agent difficult, we noted a clear temporal relationship between exposure to @entity10 and the development of @entity4 . Furthermore, according to the available literature, it is less likely that a @entity11 would be caused by either @entity9 or trastuzumab. In conclusion, clinicians should be aware of the potentially life-threatening risk of @entity4 following @entity10 treatment. If @entity10 is halted early and the @entity1 has good lung reserve, @entity4 can be reversed with high-dose @entity6 administration.

title: XXXX -induced pneumonitis in @entity1 with @entity0 : case series and review of the literature.

answer: @entity10


abstract: UNASSIGNED: @entity7 plus @entity9 followed by @entity10 is a common adjuvant treatment for high-risk @entity0 . It has been associated with @entity4 in several case reports. We describe three @entity1 in whom @entity5 developed immediately after the first @entity10 exposure and worsened clinically over time. All reported dyspnoea, @entity2 and progressive @entity8 . Imaging revealed diffuse @entity4 . Other causes of @entity11 were excluded with laboratory work-up, imaging, biopsy studies and results of antibiotic treatment. The @entity11 was reversed only after administration of high-dose @entity3 , an empirical treatment previously reported to be beneficial in similar cases. Although chemotherapy using concomitant or sequential drugs may make identification of the toxic agent difficult, we noted a clear temporal relationship between exposure to @entity10 and the development of @entity4 . Furthermore, according to the available literature, it is less likely that a @entity11 would be caused by either @entity9 or trastuzumab. In conclusion, clinicians should be aware of the potentially life-threatening risk of @entity4 following @entity10 treatment. If @entity10 is halted early and the @entity1 has good lung reserve, @entity4 can be reversed with high-dose @entity6 administration.

title: @entity10 -induced pneumonitis in XXXX with @entity0 : case series and review of the literature.

answer: @entity1


abstract: UNASSIGNED: Comprehensive analysis of alterations in gene expression along with neoplastic transformation in @entity0 cells provides valuable information about the molecular mechanisms underlying transformation. To further address these questions, we performed whole transcriptome analysis to the @entity0 mesenchymal stem cell line, UE6E7T-3, which was immortalized with @entity7 and @entity6 E6/E7 genes, in association with progress of transformation in these cells. At early stages of culture, UE6E7T-3 cells preferentially lost one copy of chromosome 13, as previously described; in addition, @entity1 suppressor genes, DNA repair genes, and apoptosis-activating genes were overexpressed. After the loss of chromosome 13, additional @entity3 that drove progressive transformation, were observed. At this stage, the cell line expressed oncogenes as well as genes related to anti-apoptotic functions, cell-cycle progression, and @entity5 ( @entity5 ); these pro-tumorigenic changes were concomitant with a decrease in @entity1 suppressor gene expression. At later stages after prolong culture, the cells exhibited chromosome translocations, acquired anchorage-independent growth and @entity9 in @entity2 , ( @entity4 ) and exhibited increased expression of genes encoding growth factor and DNA repair genes, and decreased expression of adhesion genes. In particular, @entity10 ( @entity10 ), which encodes a cell-surface proteoglycan that might be a biomarker for @entity4 , was expressed at high levels in association with transformation. Patched ( @entity8 ), the cell surface receptor for hedgehog (Hh) signaling, was also significantly overexpressed and co-localized with @entity10 . Knockdown of @entity10 expression decreased cell proliferation, suggesting that it plays a key role in growth in U3-DT cells (transformants derived from UE6E7T-3 cells) through the Hh signaling pathway. Thus, the UE6E7T-3 cell culture model is a useful tool for assessing the functional contribution of genes showed by expression profiling to the neoplastic transformation of @entity0 fibroblasts and @entity0 mesenchymal stem cells (hMSC).

title: Transcriptional Dynamics of Immortalized XXXX Mesenchymal Stem Cells during Transformation.

answer: @entity0


abstract: BACKGROUND: @entity0 who are overweight or @entity2 are at risk for @entity3 , including @entity4 (birth weight >= 4,000   g), that may contribute to breastfeeding initiation failure. This study examined factors associated with breastfeeding initiation among @entity2 @entity0 without @entity1 who delivered macrosomic @entity0 . STUDY DESIGN AND METHODS: A retrospective chart review was conducted from 2008 to 2011. Based on prepregnancy body mass index (in kg/m(2)), @entity0 were classified as normal (18-24.9), overweight (25-29.9), @entity2 (30-34.9), @entity2 (35-39.9), and @entity2 (>= 40). Intention to breastfeed was ascertained prenatally, and breastfeeding initiation was defined if at discharge >= 50% of the @entity0 feedings were breastmilk. RESULTS: Twenty-nine percent of the population was overweight, 23% @entity2 , 14% @entity2 , and 12% @entity2 . Intention to breastfeed was similar among normal-weight, overweight, @entity2 @entity0 but was significantly lower for those who were @entity2 (p<0.05). Breastfeeding initiation was 75% for normal-weight, 72% for overweight, 71% for @entity2 , 66% for @entity2 , and 53% for @entity2 @entity0 (p<0.05). Among @entity0 who intended to breastfeed, breastfeeding initiation was uniformly high: 94% for normal-weight, 93% for overweight, 95% for @entity2 , 92% for @entity2 , and 87% for @entity2 @entity0 . CONCLUSIONS: Intention to breastfeed as well as breastfeeding initiation was significantly lower for @entity2 @entity0 . Lack of intention to breastfeed declared during the antepartum period by @entity2 @entity0 highlights a need as well as an opportunity for intervention.

title: Breastfeeding Initiation Among Macrosomic XXXX Born to Obese Nondiabetic Mothers.

answer: @entity0


abstract: OBJECTIVE: To evaluate diagnostic performance of the emotional domain of the VoiSS questionnaire compared with the Hospital Anxiety and @entity2 Scale (HADS). DESIGN: Cross sectional questionnaire study. SETTING: Tertiary referral centre voice clinic. @entity0 : 210 consecutive voice clinic @entity0 . MAIN OUTCOME MEASURES: Screening with VoiSS and HADS questionnaires. Paired comparison, correlation, multinomial logistic regression and receiver operating characteristic (ROC) curve analysis. RESULTS: 177 returned complete datasets. 96 @entity0 (54.2%) had functional @entity5 and 81(45.8%) had @entity3 . Mean total VoiSS score =39.7/120 (standard deviation (SD) 22.2). Mean emotional VoiSS subscale =7.6/22 (SD 7.5). Mean HAD @entity1 =6.5/21 (SD 5.2) and @entity2 mean =7.1/21 (SD 4.8). There were 35 (20%) borderline @entity2 scores and 30 (17%) scores considered positive for "caseness". There was strong correlation between emotional VoiSS and HADS @entity1 (Spearman's Rho= 0.68, p < .001) and @entity2 (Spearman's Rho= 0.62, p < .001). ROC curve analysis exhibited significant association between emotional VoiSS and HADS "caseness" (area under curve =0.88). In addition functional @entity5 @entity0 had lower mean VoiSS and HADS scores than @entity0 with  identifiable @entity6 . CONCLUSION: The VoiSS emotional subscale strongly correlates with HADS @entity1 and @entity2 scores and could be used as a measure of @entity4 . This could allow targeted psychological strategies, without additional psychometric questionnaires. @entity5 has less association with @entity4 than certain organic laryngological disorders. This article is protected by copyright. All rights reserved.

title: Pragmatic detection of XXXX and @entity2 in a prospective cohort of voice outpatient clinic attenders.

answer: @entity1


abstract: OBJECTIVE: To evaluate diagnostic performance of the emotional domain of the VoiSS questionnaire compared with the Hospital Anxiety and @entity2 Scale (HADS). DESIGN: Cross sectional questionnaire study. SETTING: Tertiary referral centre voice clinic. @entity0 : 210 consecutive voice clinic @entity0 . MAIN OUTCOME MEASURES: Screening with VoiSS and HADS questionnaires. Paired comparison, correlation, multinomial logistic regression and receiver operating characteristic (ROC) curve analysis. RESULTS: 177 returned complete datasets. 96 @entity0 (54.2%) had functional @entity5 and 81(45.8%) had @entity3 . Mean total VoiSS score =39.7/120 (standard deviation (SD) 22.2). Mean emotional VoiSS subscale =7.6/22 (SD 7.5). Mean HAD @entity1 =6.5/21 (SD 5.2) and @entity2 mean =7.1/21 (SD 4.8). There were 35 (20%) borderline @entity2 scores and 30 (17%) scores considered positive for "caseness". There was strong correlation between emotional VoiSS and HADS @entity1 (Spearman's Rho= 0.68, p < .001) and @entity2 (Spearman's Rho= 0.62, p < .001). ROC curve analysis exhibited significant association between emotional VoiSS and HADS "caseness" (area under curve =0.88). In addition functional @entity5 @entity0 had lower mean VoiSS and HADS scores than @entity0 with  identifiable @entity6 . CONCLUSION: The VoiSS emotional subscale strongly correlates with HADS @entity1 and @entity2 scores and could be used as a measure of @entity4 . This could allow targeted psychological strategies, without additional psychometric questionnaires. @entity5 has less association with @entity4 than certain organic laryngological disorders. This article is protected by copyright. All rights reserved.

title: Pragmatic detection of @entity1 and XXXX in a prospective cohort of voice outpatient clinic attenders.

answer: @entity2


abstract: @entity3 ( @entity3 ) are a high prevalence disease. It is estimated that about 20% of the general population is affected by @entity3 . Some of those lesions can progress till @entity1 , while others behave in a benign fashion. In @entity5 of the pancreas can be considered as the pancreatic analogon to @entity4 . Treatment of these precursor lesions at an early stage can potentially reduce @entity3 mortality and introduce a new "era" of preemptive pancreatic surgery. However, only few of those lesions have an @entity2 . The accuracy of preoperative diagnosis, i.e., the distinction between the various @entity3 is around 60%, and the ability to predict the future outcome is also less accurate. For this reason, a significant number of @entity0 are currently over-treated with an unnecessary, high-risk surgery. Furthermore, the majority of @entity0 with PCN are on life-long follow-up with imaging modality, which has huge cost implications for the Health Care System for limited benefits considering that a significant proportion of @entity3 are or behave like benign lesions. The current guidelines for the diagnosis and management of @entity3 are more based on expert opinion than on evidence. For all those reasons, the management of @entity1 remains a controversial area of pancreatology. On one hand, the detection of @entity3 and the surgical treatment of pre-cancerous @entity1 can be considered a big opportunity to reduce @entity3 related mortality. On the other hand, @entity3 are associated with a considerable risk of under- or over- treatment of @entity0 and incur high costs for the Health Care System.

title: XXXX of the pancreas: Opportunities and risks.

answer: @entity1


abstract: BACKGROUND: In the past decade, several studies have focused on the treatment needs of female inmates with @entity4 problems. An important finding has been that these @entity0 are more likely to report histories of sexual, physical, and emotional abuse-at rates varying from 77% to 90%. The @entity1 resulting from this kind of abuse is a key contributing factor in @entity2 in adolescence and subsequent delinquency, @entity4 , and criminality in adulthood. METHODS: This was a retrospective clinical study. A convenience sample of 112 @entity0 who entered the program's treatment groups consecutively for one year form part of the study. Information on traumatic events was obtained using some questions from the Initial @entity1 Review. It explores whether the @entity0 experienced physical abuse, @entity3 , disasters, automobile accidents, or witnessed violence under the age of 18. It also examines experiences as an adult, including @entity3 , attacks by others who are not intimate partners, and abuse by authorities. RESULTS: Revictimization in @entity3 was found in 78.1% of @entity0 . Significant differences were identified between @entity0 who had experienced a traumatic sexual event from a @entity0 five years their senior before the age of 18 and then suffered from @entity3 as an adult, and @entity0 who had never undergone either of these events (x(2)   =   11.3, df 112/1, p   =   <.001). In physical abuse, the figure was 82.17%. Differences were observed between @entity0 who were revictimized through physical abuse before and after the age of 18 (x(2)   =   5.91, df 112/1, p   =   <.01), and those who had not experienced any kind of revictimization. Significant differences were found between @entity0 who had suffered a traumatic sexual event as a @entity0 and subsequently physical violence from their parents, and @entity0 who had not undergone either of these events (x(2)   =   3.48, df 112/1, p   =   <.05). CONCLUSIONS: Investment in treatment in these areas during the prison sentence and after release may contribute to preventing these @entity0 from become repeat offenders. Creating sources of work and halfway houses that continue the program to prevent relapses into substance use can help defend the @entity0 rights of this group of @entity0 and achieve social justice.

title: Traumatic experiences and re-victimization of female inmates undergoing treatment for XXXX .

answer: @entity4


abstract: BACKGROUND: Thrombomodulin is a thrombin receptor on the endothelial cell surface that plays an important role in the regulation of @entity3 . The purpose of this study was to evaluate the efficacy and safety of treatment with recombinant @entity0 soluble thrombomodulin (rhTM) for @entity0 with @entity3 ( @entity3 ) associated with gastroenterological surgery. MATERIALS AND METHODS: From April 2011-September 2013, 201 @entity0 with @entity3 associated with gastroenterological surgery were treated in 16 institutions in Kumamoto, Japan. The @entity0 were diagnosed according to the Japanese Association for Acute Medicine @entity3 scoring system. The clinical course, mortality rate at 28  d, and adverse events were evaluated retrospectively. RESULTS: Forty-five @entity0 were excluded because they did not meet the Japanese Association for Acute Medicine @entity3 criteria or had an insufficient duration of drug administration. Thus, 156 @entity0 were analyzed. Of these @entity0 , 107 received rhTM at the discretion of the attending surgeon and 49 did not. The most common reason for surgery in both groups was @entity1 due to perforation of the colon. Within 7  d, the platelet count, prothrombin time-international normalized ratio, @entity3 score, neutrophil count, and @entity2 level significantly improved in the rhTM group compared with those in the control. Treatment with rhTM was significantly associated with reduced inhospital mortality at 28  d. The incidence of adverse events did not differ between the two groups. CONCLUSIONS: Therapy with rhTM may be associated with reduced inhospital mortality in @entity0 with septic @entity3 associated with gastroenterological surgery without increasing adverse events.

title: Recombinant soluble thrombomodulin for postoperative disseminated XXXX .

answer: @entity3


abstract: UNASSIGNED: The Internet is expected to innovate healthcare, in particular @entity0 -centredness of care. Within fertility care, information provision, communication with healthcare providers and support from peers are important components of @entity0 -centred care. An online @entity1 community added to an in vitro fertilisation or IVF clinic's practice provides tools to healthcare providers to meet these. This study's online @entity1 community facilitates peer-to-peer support, information provision to @entity0 and @entity0 provider communication within one clinic. Unfortunately, these interventions often fail to become part of clinical routines. The analysis of a first introduction into usual care can provide lessons for the implementation in everyday health practice. The aim was to explore experiences of professionals and @entity0 with the implementation of an @entity1 community into a clinic's care practice. We performed semi-structured interviews with both professionals and @entity0 to collect these experiences. These interviews were analyzed using the Normalisation Process Model. Assignment of a community manager, multidisciplinary division of tasks, clear instructions to staff in advance and periodical evaluations could contribute to the integration of this online community. Interviews with @entity0 provided insights into the possible impact on daily care. This study provides lessons to healthcare providers on the implementation of an online @entity1 community into their practice.

title: Lessons learned from the implementation of an online XXXX community into an IVF clinic's daily practice.

answer: @entity1


abstract: UNASSIGNED: Anaesthetic preconditioning (APC) and @entity1 preconditioning (IPC) ameliorate @entity3 -reperfusion (I/R) injury and are important for regulating @entity7 . MicroRNAs (miRNAs) are short, noncoding RNA molecules of 21-23 @entity4 in length, and are currently under intensive investigation regarding their ability to regulate gene expression in a wide range of species. miRNA activity is involved in controlling a wide range of biological functions and processes. We evaluated whether APC and IPC are mediated by the same miRNAs by performing comprehensive miRNA screening experiments in a @entity0 model of @entity7 . Twenty-one @entity0 were randomly divided into three groups (n = 7/group): control (mock preconditioning), APC, and IPC. Control @entity0 were subjected to 60 min of @entity2 followed by 4 h of reperfusion, whereas the APC and IPC groups were preconditioned with 2% @entity5 and @entity2 for 10 min prior to @entity1 -reperfusion, respectively. Liver samples were collected to measure miRNA levels after 3 h of reperfusion, and gene networks and canonical pathways were identified using Ingenuity Pathway Analysis (IPA). Blood samples were collected to measure the levels of @entity8 aminotransferase (AST) and @entity6 aminotransferase (ALT). Although haemodynamic parameters did not vary among the groups, AST and ALT levels were significantly higher in the control group than in the APC and IPC groups. Comprehensive miRNA screening experiments revealed that most miRNAs altered in the APC group were common to those in the IPC group. IPA identified five miRNAs related to the Akt-glycogen synthase kinase-3b ( @entity9 )- @entity10 pathway that were significantly affected by both preconditioning strategies. The application of either APC or IPC to ameliorate @entity7 results in expression of several common miRNAs that are related to the Akt-GSK- @entity10 pathway.

title: Identical MicroRNAs Regulate Liver Protection during Anaesthetic and Ischemic Preconditioning in XXXX : An animal study.

answer: @entity0


abstract: INTRODUCTION: @entity1 is thought to be a clonal event whereby a single cell initiates the development of a new @entity2 at a distant site. However the degree to which primary and @entity1 differ on a molecular level remains unclear. To further evaluate these concepts, we used next generation sequencing (NGS) to assess the molecular composition of paired primary and metastatic @entity3 tissue specimens. METHODS: 468 @entity3 samples from a large personalized medicine initiative were assessed by targeted gene sequencing of 1,321 individual genes. Eighteen @entity0 produced genomic profiles for 17 paired primary:metastatic (and 2 metastatic:metastatic) specimens. RESULTS: An average of 33.3 mutations/ @entity2 were concordant (shared) between matched samples, including common well-known genes ( @entity8 , @entity5 , @entity4 ). An average of 2.3 mutations/ @entity2 were discordant (unshared) among paired sites. @entity5 mutational status was always concordant. The overall concordance rate for mutations was 93.5%; however, nearly all (18/19 (94.7%)) paired @entity2 showed at least one mutational discordance. Mutations were seen in: @entity10 , the largest gene (5 discordant pairs), @entity14 , @entity8 , @entity15 , @entity13 , @entity4 , and @entity11 (2 discordant pairs), @entity7 , @entity9 , @entity6 , @entity12 , and 66 others (1 discordant pair). CONCLUSIONS: Whereas primary and @entity1 displayed little variance overall, co-evolution produced incremental mutations in both. These results suggest that while biopsy of the @entity2 alone is likely sufficient in the chemotherapy-na  ve @entity0 , additional biopsies of primary or metastatic disease may be necessary to precisely tailor therapy following chemotherapy resistance or insensitivity in order to adequately account for @entity2 evolution.

title: Co-Evolution of Somatic Variation in Primary and Metastatic XXXX May Expand Biopsy Indications in the Molecular Era.

answer: @entity3


abstract: Dermatophytes are among the common causes of @entity1 in the community. Classical diagnostic tests for @entity2 have some disadvantages such as failure of direct microscopy in species differentiation and culture methods being time consuming and having low sensitivity. The aim of this study was to investigate the performance of polymerase chain reaction (PCR) in the identification of dermatophytes directly from the clinical samples and the cultures. A total of 123 samples that comprise 63 skin and 60 nail scrapings obtained from 110 @entity0 (69 female, 41 male; age range: 4-82 years) who were prediagnosed as @entity2 , were included in the study. Samples were examined with routine direct microscopy, culture and two different nested PCR (nPCR) protocols. The first was a pan-dermatophyte nPCR protocol targeting chitin synthase gene (CHS-1) of dermatophytes and the second was a nPCR protocol which targets specific ITS-1 genes of @entity3 and @entity4 . Similar PCR methods were also applied to cultivated strains. Sequence analysis was performed for the samples that yielded positive results in pan-dermatophyte nPCR and negative results in @entity3 / @entity4 - specific nPCR. Hyphae and/or spore structures were observed in 62 (50%) samples with direct microscopic examination and dermatophytes were isolated in 30 (24%) samples. Twenty-eight of the isolates grown in culture were identified as @entity3 , and two as @entity4 with @entity3 / @entity4 -specific nPCR protocol. In direct application, 67 (55%) of the clinical samples were found positive with pan-dermatophyte nPCR and 65 (53%) were positive with @entity3 / @entity4 -specific nPCR. Samples which were negative in direct microscopic examination were also negative in culture. Nine of them were found positive with pan-dermatophyte nPCR and eight were positive with @entity3 / @entity4 -specific nPCR. Two of the 30 samples which were positive in culture were negative in direct pan-dermatophyte nPCR, and one of them was negative in @entity3 / @entity4 -specific nPCR. Three samples which were positive by pan-dermatophyte nPCR, gave negative result with @entity3 / @entity4 -specific nPCR. Sequence analysis was performed for these three samples and all were identified as @entity3 . In evaluation of concordance between the methods, the agreement of direct microscopy and culture was moderate (kappa value; k= 0.48), the agreement of direct microscopy and both protocols of nPCR was high (k= 0.78) and the agreement of both nPCR protocols with each other was excellent (k= 0.93). Our data indicated that two different nPCR methods used for the laboratory diagnosis of @entity2 yielded higher positivity in less time than the culture method. In conclusion, nPCR was considered to be useful in identification of @entity2 from either direct clinical samples or culture-isolated strains.

title: [The use of polymerase chain reaction in laboratory diagnosis of XXXX ].

answer: @entity2


abstract: Between 1968 and 1977 in Austria 38.6 per cent of all deaths due to electricity were caused by high voltages (in the decade before only 23.5 per cent). Victims are mostly middle-aged @entity0 . Three of four victims still die on the scene of accident. Based on 16 cases of fatal high tension electrocution some autopsy findings are discussed from the medico-legal point of view. One of four cases showed entrance and exit points of current resembling "typical" electric marks (as they are known from exposure to domestic voltages). In one case the marks produced by a 20,000 volts overhead-supply were so small that they have been overlooked by the medical examiner. Half the bodies exhibited major surface burns from involvement in electric arcs. About one third of the fatal accidents was accompanied by secondary mechanical @entity1 . Asphyxial findings ( @entity4 in the eyelids and conjunctivae, as well as under the pleura and the epicardium, etc.) were noticed in two cases. Such unspecific signs of suffocation also are met, if @entity2 is caused by domestic voltages (in our material the frequency amounts to 13 per cent). One case-study deals with special morphological findings after long-time exposure to high tension electricity: besides charrings and severance of limbs also fat and @entity7 into the right ventricle (due to local tissue heating) was observed. By emission spectroscopy of residues on the @entity5 wire @entity3 and @entity6 originating from melted bones could be detected.

title: [Pathomorphological constellation in XXXX resulting from high voltage electricity].

answer: @entity2


abstract: OBJECTIVES: To identify risk factors of 30-day readmissions due to ambulatory care-sensitive conditions (ACSCs) for @entity1 Medicare home healthcare beneficiaries in order to improve transition from hospital-based care to home healthcare. STUDY DESIGN: We analyzed @entity1 Medicare beneficiaries who received home healthcare within 14 days of hospital discharges in 2009. The unit of analysis is the home health episode for post acute care. METHODS: The conceptual framework was guided by Andersen's Behavioral Model of Health Services. Data sources included: Medicare Beneficiary Summary File, Medicare Provider Analysis Review, Outcome Assessment Information Set, Home Health Agency Research Identifiable File, Hospital Readmissions Reduction Program Supplemental Data File, Provider of Services File, and Area Health Resources File. The dependent variable was time to first 30-day ACSC-related readmission. Proportional hazards regression was used for the statistical analyses. RESULTS: The 30-day ACSC-related readmission rate was approximately 6% in our study sample, costing the Medicare program about  62 million. Predictors of readmissions due to ACSCs within 30 days of hospital discharge were: being aged 75 to 84 years, being an African American, requiring assistance in medication management, and having 1 or more of the following clinical conditions: congestive @entity6 , @entity8 , @entity7 , @entity3 , @entity5 , fluid and electrolyte diseases, @entity4 and/or @entity2 , and pressure or stasis ulcer. @entity0 with @entity7 or @entity3 had a 40% higher risk of 30-day ACSC-related readmissions than their counterparts. CONCLUSIONS: Knowing the risk factors identified above, hospital providers can improve care planning and transition of care to the home healthcare providers.

title: Improving XXXX @entity0 transition to home healthcare: leading risk factors for 30-day readmission.

answer: @entity1